Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69


Optimizing the Care of Malignant Bowel Obstruction in Patients With Advanced Gynecologic Cancer.

Lee YC, Jivraj N, Wang L, Chawla T, Lau J, Croke J, Allard JP, Stuart-McEwan T, Nathwani K, Bowering V, Karakasis K, O'Brien C, Shlomovitz E, Ferguson SE, Buchanan S, Ng P, Cyriac S, Tinker L, Dhani N, Oza AM, Lheureux S.

J Oncol Pract. 2019 Sep 24:JOP1800793. doi: 10.1200/JOP.18.00793. [Epub ahead of print]


The DNA Repair Pathway as a Target for Novel Drugs in Gynecologic Cancers.

Lheureux S, Mirza M, Coleman R.

J Clin Oncol. 2019 Sep 20;37(27):2449-2459. doi: 10.1200/JCO.19.00347. Epub 2019 Aug 12. No abstract available.


DNA Methylation as a Robust Classifier of Epithelial Ovarian Cancer.

Ishak CA, Lheureux S, De Carvalho DD.

Clin Cancer Res. 2019 Oct 1;25(19):5729-5731. doi: 10.1158/1078-0432.CCR-19-1797. Epub 2019 Jul 23.


Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?

Bersanelli M, Iacovelli R, Buti S, Houede N, Laguerre B, Procopio G, Lheureux S, Fischer R, Negrier S, Ravaud A, Oudard S, Escudier B, Albiges L, Porta C.

Eur Urol Oncol. 2019 Jul 19. pii: S2588-9311(19)30099-9. doi: 10.1016/j.euo.2019.06.018. [Epub ahead of print]


FIGO 2018 stage IB2 (2-4 cm) Cervical cancer treated with Neo-adjuvant chemotherapy followed by fertility Sparing Surgery (CONTESSA); Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility (NEOCON-F). A PMHC, DGOG, GCIG/CCRN and multicenter study.

Plante M, van Trommel N, Lheureux S, Oza AM, Wang L, Sikorska K, Ferguson SE, Han K, Amant F.

Int J Gynecol Cancer. 2019 Jun;29(5):969-975. doi: 10.1136/ijgc-2019-000398. Epub 2019 May 17.


Epithelial ovarian cancer: Evolution of management in the era of precision medicine.

Lheureux S, Braunstein M, Oza AM.

CA Cancer J Clin. 2019 Jul;69(4):280-304. doi: 10.3322/caac.21559. Epub 2019 May 17. Review.


Going to extremes: determinants of extraordinary response and survival in patients with cancer.

Saner FAM, Herschtal A, Nelson BH, deFazio A, Goode EL, Ramus SJ, Pandey A, Beach JA, Fereday S, Berchuck A, Lheureux S, Pearce CL, Pharoah PD, Pike MC, Garsed DW, Bowtell DDL.

Nat Rev Cancer. 2019 Jun;19(6):339-348. doi: 10.1038/s41568-019-0145-5. Review.


Epithelial ovarian cancer.

Lheureux S, Gourley C, Vergote I, Oza AM.

Lancet. 2019 Mar 23;393(10177):1240-1253. doi: 10.1016/S0140-6736(18)32552-2. Review.


Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations.

Madariaga A, Lheureux S, Oza AM.

Cancers (Basel). 2019 Mar 23;11(3). pii: E416. doi: 10.3390/cancers11030416. Review.


An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE).

Clouthier DL, Lien SC, Yang SYC, Nguyen LT, Manem VSK, Gray D, Ryczko M, Razak ARA, Lewin J, Lheureux S, Colombo I, Bedard PL, Cescon D, Spreafico A, Butler MO, Hansen AR, Jang RW, Ghai S, Weinreb I, Sotov V, Gadalla R, Noamani B, Guo M, Elston S, Giesler A, Hakgor S, Jiang H, McGaha T, Brooks DG, Haibe-Kains B, Pugh TJ, Ohashi PS, Siu LL.

J Immunother Cancer. 2019 Mar 13;7(1):72. doi: 10.1186/s40425-019-0541-0.


Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients.

Rodriguez-Freixinos V, Lheureux S, Mandilaras V, Clarke B, Dhani NC, Mackay H, Butler MO, Wang L, Siu LL, Kamel-Reid S, Stockley T, Bedard PL, Oza AM.

Gynecol Oncol. 2019 May;153(2):304-311. doi: 10.1016/j.ygyno.2019.02.005. Epub 2019 Feb 18.


TP53 mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses.

Mandilaras V, Garg S, Cabanero M, Tan Q, Pastrello C, Burnier J, Karakasis K, Wang L, Dhani NC, Butler MO, Bedard PL, Siu LL, Clarke B, Shaw PA, Stockley T, Jurisica I, Oza AM, Lheureux S.

Int J Gynecol Cancer. 2019 Jan 18. pii: ijgc-2018-000087. doi: 10.1136/ijgc-2018-000087. [Epub ahead of print]


Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors.

Yang SYC, Lheureux S, Karakasis K, Burnier JV, Bruce JP, Clouthier DL, Danesh A, Quevedo R, Dowar M, Hanna Y, Li T, Lu L, Xu W, Clarke BA, Ohashi PS, Shaw PA, Pugh TJ, Oza AM.

Genome Med. 2018 Oct 31;10(1):81. doi: 10.1186/s13073-018-0590-x.


FDG PET/CT for assessing tumour response to immunotherapy : Report on the EANM symposium on immune modulation and recent review of the literature.

Aide N, Hicks RJ, Le Tourneau C, Lheureux S, Fanti S, Lopci E.

Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):238-250. doi: 10.1007/s00259-018-4171-4. Epub 2018 Oct 5. Review.


A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium.

Lheureux S, Tinker A, Clarke B, Ghatage P, Welch S, Weberpals JI, Dhani NC, Butler MO, Tonkin K, Tan Q, Tan DSP, Brooks K, Ramsahai J, Wang L, Pham NA, Shaw PA, Tsao MS, Garg S, Stockley T, Oza AM.

Clin Cancer Res. 2018 Dec 15;24(24):6168-6174. doi: 10.1158/1078-0432.CCR-18-1244. Epub 2018 Aug 14.


Malignant Bowel Obstruction in Advanced Gynecologic Cancers: An Updated Review from a Multidisciplinary Perspective.

Lee YC, Jivraj N, O'Brien C, Chawla T, Shlomovitz E, Buchanan S, Lau J, Croke J, Allard JP, Dhar P, Laframboise S, Ferguson SE, Dhani N, Butler M, Ng P, Stuart-McEwan T, Savage P, Tinker L, Oza AM, Lheureux S.

Obstet Gynecol Int. 2018 May 17;2018:1867238. doi: 10.1155/2018/1867238. eCollection 2018. Review.


The role of niraparib for the treatment of ovarian cancer.

Ethier JL, Lheureux S, Oza AM.

Future Oncol. 2018 Oct;14(25):2565-2577. doi: 10.2217/fon-2018-0101. Epub 2018 Jun 1. Review.


Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer.

Colombo I, Lheureux S, Oza AM.

Drug Des Devel Ther. 2018 Mar 21;12:605-617. doi: 10.2147/DDDT.S130809. eCollection 2018. Review.


Biomarker Discovery from We to Me: Is Learning from Each Patient a New Approach?

Lheureux S.

Clin Cancer Res. 2018 Jul 15;24(14):3233-3235. doi: 10.1158/1078-0432.CCR-18-0380. Epub 2018 Mar 26.


Emerging growth factor receptor antagonists for ovarian cancer treatment.

Bonilla L, Oza A, Lheureux S.

Expert Opin Emerg Drugs. 2018 Mar;23(1):1-16. doi: 10.1080/14728214.2018.1446942. Epub 2018 Mar 12. Review.


Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: A NCI clinical trials planning meeting report.

Lheureux S, McCourt C, Rimel BJ, Duska L, Fleming G, Mackay H, Mutch D, Temkin SM, Lynn J, Kohn EC.

Gynecol Oncol. 2018 Feb 22. pii: S0090-8258(18)30124-0. doi: 10.1016/j.ygyno.2018.02.005. [Epub ahead of print] Review.


Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma.

Lheureux S, Butler MO, Clarke B, Cristea MC, Martin LP, Tonkin K, Fleming GF, Tinker AV, Hirte HW, Tsoref D, Mackay H, Dhani NC, Ghatage P, Weberpals J, Welch S, Pham NA, Motta V, Sotov V, Wang L, Karakasis K, Udagani S, Kamel-Reid S, Streicher HZ, Shaw P, Oza AM.

JAMA Oncol. 2018 Jul 12;4(7):e173776. doi: 10.1001/jamaoncol.2017.3776. Epub 2018 Jul 12.


Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers.

Lee YC, Milne RL, Lheureux S, Friedlander M, McLachlan SA, Martin KL, Bernardini MQ, Smith C, Picken S, Nesci S, Hopper JL, Phillips KA; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).

Eur J Cancer. 2017 Oct;84:114-120. doi: 10.1016/j.ejca.2017.07.004. Epub 2017 Aug 10.


Molecular imaging in drug development: Update and challenges for radiolabeled antibodies and nanotechnology.

Colombo I, Overchuk M, Chen J, Reilly RM, Zheng G, Lheureux S.

Methods. 2017 Nov 1;130:23-35. doi: 10.1016/j.ymeth.2017.07.018. Epub 2017 Jul 23. Review.


Resisting RECIST-Uniformity Versus Clinical Validity.

Wilson MK, Friedlander ML, Lheureux S, Small W Jr, Poveda A, Pujade-Lauraine E, Karakasis K, Bacon M, Bowering V, Chawla T, Oza AM.

Int J Gynecol Cancer. 2017 Oct;27(8):1619-1627. doi: 10.1097/IGC.0000000000001062.


Updates and current challenges in microRNA research for personalized medicine in ovarian cancer.

Mandilaras V, Vernon M, Meryet-Figuière M, Karakasis K, Lambert B, Poulain L, Oza A, Denoyelle C, Lheureux S.

Expert Opin Biol Ther. 2017 Aug;17(8):927-943. doi: 10.1080/14712598.2017.1340935. Epub 2017 Jun 22. Review.


Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach.

Samimi G, Bernardini MQ, Brody LC, Caga-Anan CF, Campbell IG, Chenevix-Trench G, Couch FJ, Dean M, de Hullu JA, Domchek SM, Drapkin R, Spencer Feigelson H, Friedlander M, Gaudet MM, Harmsen MG, Hurley K, James PA, Kwon JS, Lacbawan F, Lheureux S, Mai PL, Mechanic LE, Minasian LM, Myers ER, Robson ME, Ramus SJ, Rezende LF, Shaw PA, Slavin TP, Swisher EM, Takenaka M, Bowtell DD, Sherman ME.

J Clin Oncol. 2017 Jul 10;35(20):2329-2337. doi: 10.1200/JCO.2016.70.3439. Epub 2017 Apr 11.


Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician.

Lheureux S, Denoyelle C, Ohashi PS, De Bono JS, Mottaghy FM.

Eur J Nucl Med Mol Imaging. 2017 Aug;44(Suppl 1):41-54. doi: 10.1007/s00259-017-3695-3. Epub 2017 Apr 10. Review.


Niraparib for the treatment of ovarian cancer.

Kanjanapan Y, Lheureux S, Oza AM.

Expert Opin Pharmacother. 2017 Apr;18(6):631-640. doi: 10.1080/14656566.2017.1297423. Epub 2017 Apr 7. Review.


Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.

Lheureux S, Lai Z, Dougherty BA, Runswick S, Hodgson DR, Timms KM, Lanchbury JS, Kaye S, Gourley C, Bowtell D, Kohn EC, Scott C, Matulonis U, Panzarella T, Karakasis K, Burnier JV, Gilks CB, O'Connor MJ, Robertson JD, Ledermann J, Barrett JC, Ho TW, Oza AM.

Clin Cancer Res. 2017 Aug 1;23(15):4086-4094. doi: 10.1158/1078-0432.CCR-16-2615. Epub 2017 Feb 21.


Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis.

Ethier JL, Desautels DN, Templeton AJ, Oza A, Amir E, Lheureux S.

Gynecol Oncol. 2017 Jun;145(3):584-594. doi: 10.1016/j.ygyno.2017.02.026. Epub 2017 Feb 20. Review.


Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.

Lheureux S, Bruce JP, Burnier JV, Karakasis K, Shaw PA, Clarke BA, Yang SY, Quevedo R, Li T, Dowar M, Bowering V, Pugh TJ, Oza AM.

J Clin Oncol. 2017 Apr 10;35(11):1240-1249. doi: 10.1200/JCO.2016.71.3677. Epub 2017 Feb 21.


Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC).

Spreafico A, Oza AM, Clarke BA, Mackay HJ, Shaw P, Butler M, Dhani NC, Lheureux S, Wilson MK, Welch S, Zhang T, Yu C, Stockley T, Siu LL, Kamel-Reid S, Bedard PL.

Gynecol Oncol. 2017 Feb;144(2):250-255. doi: 10.1016/j.ygyno.2016.12.002. Epub 2017 Jan 3.


Treatment strategies for endometrial cancer: current practice and perspective.

Lee YC, Lheureux S, Oza AM.

Curr Opin Obstet Gynecol. 2017 Feb;29(1):47-58. doi: 10.1097/GCO.0000000000000338. Review.


Paradigm Shift in the Management Strategy for Epithelial Ovarian Cancer.

Fujiwara K, McAlpine JN, Lheureux S, Matsumura N, Oza AM.

Am Soc Clin Oncol Educ Book. 2016;35:e247-57. doi: 10.14694/EDBK_158675. Review.


Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention.

Karakasis K, Burnier JV, Bowering V, Oza AM, Lheureux S.

Front Oncol. 2016 May 11;6:119. doi: 10.3389/fonc.2016.00119. eCollection 2016. Review.


Towards a new standardized method for circulating miRNAs profiling in clinical studies: Interest of the exogenous normalization to improve miRNA signature accuracy.

Vigneron N, Meryet-Figuière M, Guttin A, Issartel JP, Lambert B, Briand M, Louis MH, Vernon M, Lebailly P, Lecluse Y, Joly F, Krieger S, Lheureux S, Clarisse B, Leconte A, Gauduchon P, Poulain L, Denoyelle C.

Mol Oncol. 2016 Aug;10(7):981-92. doi: 10.1016/j.molonc.2016.03.005. Epub 2016 Apr 2.


Endometrial cancer-targeted therapies myth or reality? Review of current targeted treatments.

Lheureux S, Oza AM.

Eur J Cancer. 2016 May;59:99-108. doi: 10.1016/j.ejca.2016.02.016. Epub 2016 Mar 25. Review.


A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium.

Lheureux S, Oza AM, Laurie SA, Halford R, Jonker D, Chen E, Keller D, Bourade V, Wang L, Doyle L, Siu LL, Goel R.

Br J Cancer. 2015 Dec 1;113(11):1534-40. doi: 10.1038/bjc.2015.343. Epub 2015 Nov 10.


Germline BRCA1/2 testing practices in ovarian cancer: Current state and opportunities for new directions.

Lheureux S, Karakasis K, Harter P, Scott C, Bacon M, Bryce J, Le Fur N, Pujade-Lauraine E, Oza AM.

Gynecol Oncol. 2016 Jan;140(1):90-4. doi: 10.1016/j.ygyno.2015.10.010. Epub 2015 Oct 22.


How to assess the potential interest of aspirin in ovarian cancer?

Lheureux S, Karakasis K, Oza AM.

Cancer Epidemiol. 2015 Oct;39(5):790-1. doi: 10.1016/j.canep.2015.07.002. Epub 2015 Jul 16. No abstract available.


Ovarian cancer treatment: The end of empiricism?

Lheureux S, Karakasis K, Kohn EC, Oza AM.

Cancer. 2015 Sep 15;121(18):3203-11. doi: 10.1002/cncr.29481. Epub 2015 Jun 10. Review.


Cancer precursor lesions in the BRCA population at the time of prophylactic salpingo-oophorectomy: Accuracy of assessment and potential surrogate marker for prevention.

Lheureux S, Shaw PA, Karakasis K, Oza AM.

Gynecol Oncol. 2015 Aug;138(2):235-7. doi: 10.1016/j.ygyno.2015.06.014. Epub 2015 Jun 10. No abstract available.


Safety evaluation of olaparib for treating ovarian cancer.

Lheureux S, Bowering V, Karakasis K, Oza AM.

Expert Opin Drug Saf. 2015 Aug;14(8):1305-16. doi: 10.1517/14740338.2015.1045875. Epub 2015 Jun 8. Review.


A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia.

Hirte H, Lheureux S, Fleming GF, Sugimoto A, Morgan R, Biagi J, Wang L, McGill S, Ivy SP, Oza AM.

Gynecol Oncol. 2015 Jul;138(1):55-61. doi: 10.1016/j.ygyno.2015.04.009. Epub 2015 Apr 17.


Targeting the microenvironment in ovarian cancer.

Lheureux S, Oza AM.

Lancet Oncol. 2015 May;16(5):485-6. doi: 10.1016/S1470-2045(15)70157-9. Epub 2015 Apr 14. No abstract available.


Non-target progression--the fine line between objectivity and subjectivity.

Lheureux S, Wilson MK, O'Malley M, Sinaei M, Oza AM.

Eur J Cancer. 2014 Dec;50(18):3271-2. doi: 10.1016/j.ejca.2014.08.021. Epub 2014 Oct 18. No abstract available.


Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma.

Lheureux S, N'Diaye M, Blanc-Fournier C, Dugué AE, Clarisse B, Dutoit S, Giffard F, Abeilard E, Briand M, Labiche A, Grellard JM, Crouet H, Martin S, Joly F, Poulain L.

Int J Cancer. 2015 Mar 1;136(5):E340-50. doi: 10.1002/ijc.29104. Epub 2014 Aug 8.


A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia.

Castonguay V, Lheureux S, Welch S, Mackay HJ, Hirte H, Fleming G, Morgan R, Wang L, Blattler C, Ivy PS, Oza AM.

Gynecol Oncol. 2014 Aug;134(2):274-80. doi: 10.1016/j.ygyno.2014.05.016. Epub 2014 May 29.


Recent and current Phase II clinical trials in endometrial cancer: review of the state of art.

Lheureux S, Wilson M, Mackay HJ.

Expert Opin Investig Drugs. 2014 Jun;23(6):773-92. doi: 10.1517/13543784.2014.907272. Epub 2014 Apr 9. Review.


Supplemental Content

Loading ...
Support Center